Myomo (MYO)
(Delayed Data from AMEX)
$3.39 USD
-0.12 (-3.42%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.39 0.00 (0.00%) 6:10 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Myomo, Inc. [MYO]
Reports for Purchase
Showing records 61 - 80 ( 118 total )
Company: Myomo, Inc.
Industry: Medical - Products
1Q:20 Sales Topped Our Estimate; Expect Postponements Of MyoPro Shipments in 2Q:20
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Lower 2020 Estimates To Reflect Postponements In MyoPro Shipments Due To COVID-19; Maintain $11 Price Target
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Follow On Offering Complete; 4Q:19 Revenue Better Than Expected; German Reimbursement Approved
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Completes Stock Split And Commences $13 Million Equity Offering
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
MYO Plans To Raise $13 Million Through An Equity Offering
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Estimate Improved Reimbursement And Expanded Distribution Will Fuel About A 90%.
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
2Q:19 Sales Grew 39%, Year Over Year; Expect Expanding Reimbursement And Distribution Will
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
We Expect Expanding Reimbursement And Distribution Will Fuel About A 90%
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Estimate Improved Reimbursement And Expanded Distribution Will Fuel About A 85% Sales CAGR
Provider: SIDOTI CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.